Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting
Abstract Background Long-term prophylactic therapy is considered the standard of care for hemophilia A patients. This study models the long-term clinical and cost outcomes of two factor VIII (FVIII) products using a pharmacokinetic (PK) simulation model in a Chinese population. Methods Head-to-head...
Main Authors: | Rong Chen, Dmitry Gultyaev, Johanna Lister, Rong Han, Nan Hu, Jean Malacan, Alexander Solms, Parth Vashi, Jamie O’Hara, Shanlian Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-08-01
|
Series: | BMC Medical Research Methodology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12874-022-01659-w |
Similar Items
-
Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
by: Beth Boulden Warren, et al.
Published: (2021-07-01) -
Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
by: Kenet G, et al.
Published: (2023-06-01) -
Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
by: Kun Huang, et al.
Published: (2022-02-01) -
Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
by: Anshu Shrestha, et al.
Published: (2021-01-01) -
Acquired Hemophilia A with Gastrointestinal Bleeding
by: Narae Park, et al.
Published: (2020-01-01)